Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

December 4, 2017December 4, 2017

Survey Helps Doctors Better Understand Therapy Choices by Chronic Lymphocytic Leukemia Patients

News

A survey of patients with chronic lymphocytic leukemia (CLL) about multiple treatment scenarios found that while their top priority is longest progression-free survival, they are willing to make sacrifices on ... Read more

November 28, 2017

Janssen to Present Data of Imbruvica’s Long-term Efficacy in Mantle Cell Lymphoma

News

Janssen‘s Imbruvica (ibrutinib) – an approved therapy for relapsed or refractory mantle cell lymphoma – continues to show promising survival outcomes in these patients, particularly among those who received the treatment ... Read more

November 14, 2017

Potential Treatment for Advanced CTCL, Mogamulizumab, Under Review in Europe

News

The European Medicines Agency (EMA) agreed to review documents supporting the approval of mogamulizumab — an antibody targeting the CCR4 protein — as a treatment for adults with cutaneous T-cell lymphoma (CTCL) who ... Read more

November 3, 2017

MorphoSys’ MOR208 Receives Breakthrough Therapy Status in US for Relapsed or Refractory DLBCL

News

The U.S. Food and Drug Administration has granted breakthrough therapy designation to MorphoSys‘ MOR208 – in combination with Revlimid (lenalidomide) – for the treatment of adult patients with relapsed or refractory diffuse ... Read more

November 1, 2017November 1, 2017

FDA Grants Accelerated Approval to Calquence for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration has approved AstraZeneca‘s Calquence (acalabrutinib) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The FDA’s accelerated ... Read more

October 24, 2017October 24, 2017

Immune Design’s G100 Receives EMA’s Orphan Drug Designation for Follicular Non-Hodgkin’s Lymphoma

News

The European Medicines Agency (EMA) has granted G100 orphan drug status for the treatment of follicular non-Hodgkin’s lymphoma, Immune Design, the drug’s developer, announced in a press release. The EMA orphan drug designation – ... Read more

September 21, 2017

NCI Grants $1.5M for Phase 3 Trial of SGX301 for Cutaneous T-cell Lymphoma

News

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded Soligenix a Small Business Innovation Research (SBIR) grant of nearly $1.5 million to support the company’s pivotal Phase 3 ... Read more

September 8, 2017September 10, 2017

FDA Places Holds on Imfinzi Trials Following Unexplained Deaths in Keytruda Trials

News

The U.S. Food and Drug Administration (FDA) has placed a partial hold on two clinical trials testing a combination of AstraZeneca‘s Imfinzi (durvalumab) with an immunomodulatory drug in lymphoma and leukemia patients. ... Read more

August 24, 2017August 24, 2017

Syros Therapy SY-1425 Wins FDA’s Orphan Drug Designation to Treat Acute Myeloid Leukemia

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to SY-1425 to treat acute myeloid leukemia (AML), said the drug’s developer, Syros Pharmaceuticals. The therapy is being tested ... Read more

August 16, 2017August 16, 2017

TGR-1202 and TG-1101 Combo Is Effective Enough Against Lymphoma to Continue Being Tested in Phase 2 Trial

News

A combination of two of TG Therapeutics’ lymphoma treatments proved effective enough to continue enrolling patients in a Phase 2b clinical trial, the company announced. But one of the two failed ... Read more